中华皮肤科杂志 ›› 2011, Vol. 44 ›› Issue (12): 889-890.

• 研究报道 • 上一篇    下一篇

激活蛋白-1在皮肌炎患者外周血单一核细胞中的表达及糖皮质激素对其表达的影响

周星,栗玉珍   

  1. 哈尔滨医科大学附属第二医院皮肤科
  • 收稿日期:2011-04-06 修回日期:2011-08-28 出版日期:2011-12-15 发布日期:2011-12-02
  • 通讯作者: 周星 E-mail:miaomiaozhou03@yahoo.com.cn
  • 基金资助:

    黑龙江省科技攻关课题

Expression of activator protein-1 in peripheral blood mononuclear cells （PBMCs） from patients with dermatomyositis and glucocorticoid effect on the expression

,li yuzhen   

  • Received:2011-04-06 Revised:2011-08-28 Online:2011-12-15 Published:2011-12-02

PDF

28

赞

摘要：

目的 探讨激活蛋白-1（AP-1）在皮肌炎患者外周血单一核细胞（PBMC）中的表达及糖皮质激素对其表达的影响。方法 分别提取15例正常人和20例皮肌炎患者（为未使用过糖皮质激素的初发患者或停止糖皮质激素治疗1个月以上者，初发12例，复发8例）的PBMC，每例的PBMC等分为2份，一份加入含80 μmol/L地塞米松和10%小牛血清的RPMI 1640培养液培养48 h后待用，另一份直接-80 ℃保存待用。用电泳迁移率改变实验检测不同组别PBMC中AP-1的活性。结果 AP-1在正常人PBMC中为低表达（灰度面积值为4.93 ± 0.15 mm2）。皮肌炎初发组和复发组患者PBMC加地塞米松前的AP-1表达（灰度面积值分别为30.23 ± 0.49 mm2和34.79 ± 0.61 mm2）均明显高于地塞米松处理后AP-1表达（灰度面积值分别为5.59 ± 0.39 mm2和5.69 ± 0.39 mm2），地塞米松处理前复发组PBMC的AP-1活性高于初发组（P ＜ 0.01）。结论 AP-1活性增强可能是导致皮肌炎炎症反应及复发的重要因素之一。糖皮质激素可以一定程度抑制AP-1活性。

关键词: 单核细胞

Abstract:

Objective To investigate the expression of activator protein-1 （AP-1） in PBMCs from patients with dermatomyositis （DM） and glucocorticoid effect on the expression. Methods PBMCs were isolated from 15 normal human controls and 20 patients （including 12 patients with primary DM who had never received glucocorticoid treatment and 8 patients with recurrent DM who had stopped glucocorticoid treatment for more than 1 month）, and classified into two parts: one was cultured in RPMI 1640 medium with dexamethasone of 80 μmol/L and 10% calf serum for 48 hours, and the other was frozen at -80 ℃ and reserved. Electrophoretic mobility shift assay （EMSA） was carried out to detect the activity of AP-1 in these cells. Results The expression （grayscale area） of AP-1 in the PBMCs from the normal controls was 4.93 ± 0.15 mm2. A significant decrease was induced by the treatment with dexamethasone in the expression （grayscale area） of AP-1 from PBMCs of patients with primary DM and those with recurrent DM （5.59 ± 0.39 vs. 30.23 ± 0.49 mm2, 5.69 ± 0.39 vs. 34.79 ± 0.61 mm2, F = 13812.64, P < 0.01）. The activity of AP-1 was statistically higher in the PBMCs from patients with recurrent DM than in those from patients with primary DM before the treatment with dexamethasone （P < 0.01）. Conclusions The enhanced activity of AP-1 may be an important factor inducing the inflammatory reaction in and recurrence of DM. Glucocorticoids may suppress the AP-1 activity to a certain degree.